Request for Hysitron TI950 TriboIndenter Nanoindenter with Raman Spectroscopy

这份建议书是为了购买Hysitron TI950 TriboIndenter/拉曼光谱仪 该系统将增加纳米级材料科学能力(例如，纳米压痕， 纳米制造)和高分辨率拉曼光谱能力(例如，化学 成分，矿物/晶体异构体)到我们目前的仪器-提供了 我们测量物理和化学性质的能力有了显著的提高 器官、组织、细胞、化合物、植入物和工程材料。实验室 对这种设备感兴趣的人参与了广泛的资助研究 项目，包括骨代谢、骨科、癌症生物学、糖尿病和 肥胖。使用Hysitron TI950系统，我们将能够测量真实材料 矿化和软组织的特性直接，不需要估计 基于宏观测试的参数，这些测试在转换到纳米尺度上存在缺陷。 此外，我们要求的特定仪器有能力收集 拉曼光谱及其纳米压痕衍生的机械性能 微运动，这将显著提高实验质量和 我们进行的测量，同时也将带来大量新的产品线 我们目前享受不到的调查和合作。有很多种 退伍军人事务部资助的印第安纳波利斯退伍军人管理局调查人员将从 收购Hysitron TI950系统，包括Dr.Robling(骨质疏松症/机械- 转导)、Allen(骨质疏松症/抗吸收药)、MOE(慢性肾脏疾病)、 Bellido(骨质疏松症/激素信号)，Roodman(多发性骨髓瘤)，Nakshatri (骨肉减少/恶病质)、Chirgwin(骨髓瘤/骨细胞)和3月(脂肪来源) 干细胞)。此外，该系统将允许这些退伍军人管理局调查人员中的每一人扩大 他们的研究计划，并开始启动新的合作与大型 印第安纳波利斯分校的生物医学工程社区，他们表达了 对这个系统有很大的兴趣。

This proposal is for the purchase of a Hysitron TI950 TriboIndenter/Raman Spectroscopy System, which will add nanoscale materials science capabilities (e.g., nanoindentation, nanofabrication) and high resolution Raman Spectroscopy capabilities (e.g., chemical composition, mineral/crystal isoforms) to our present instrumentation—providing a significant improvement in our ability to measure physical and chemical properties of organs, tissues, cells, compounds, implants, and engineered materials. The laboratories interested in this piece of equipment are involved in a wide range of funded research programs, including bone metabolism, orthopaedics, cancer biology, diabetes, and obesity. With the Hysitron TI950 system, we will be able to measure true material properties of mineralized and soft tissues directly, without the need to estimate parameters based on macro-level tests that have flawed translation to the nano-scale. In addition, the particular instrument we are requesting has the capability to collect Raman spectra and nanoindentation-derived mechanical properties from the same micro-moeity, which will significantly improve the quality of experiments and measurements that we take, and at the same time, will usher in a multitude of new lines of investigation and collaboration that we currently do not enjoy. There are numerous VA-funded investigators at the Indianapolis VA that would benefit greatly from acquisition of the Hysitron TI950 system, including Drs. Robling (osteoporosis/mechano- transduction), Allen (osteoporosis/anti-resorptives), Moe (chronic kidney disease), Bellido (osteoporosis/hormone signaling), Roodman (multiple myeloma), Nakshatri (sarcopenia/cachexia), Chirgwin (myeloma/osteocytes), and March (adipose-derived stem cells). Moreover, the system would allow each of these VA investigators to expand their research programs and begin initiating new collaborations with the large biomedical engineering community on the IU Indianapolis campus, who have expressed significant interest in the system.